Sichuan Goldstone (300434.SZ): Sustained-release sodium diclofenac tablets pass consistency evaluation.

Sichuan Goldstone (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Dier Pharmaceutical Co., Ltd. (referred to as "Dier Pharmaceutical"), recently received the approval notice for drug supplementary application issued by the National Medical Products Administration. Dier Pharmaceutical's Diclofenac Sodium Sustained-release Tablets (0.1g) passed the generic drug quality and efficacy consistency evaluation. According to the announcement, the indications for Diclofenac Sodium Sustained-release Tablets include: relieving acute exacerbations or persistent joint swelling and pain symptoms of various chronic joint diseases such as rheumatoid arthritis, osteoarthritis, spinal joint disease, gouty arthritis, and rheumatic arthritis; various soft tissue rheumatic pain, such as shoulder pain, tenosynovitis, bursitis, muscle pain, and exercise-induced injury pain; acute mild to moderate pain such as postoperative, traumatic, overuse pain, primary dysmenorrhea, toothache, headache, etc.